Breaking News, Collaborations & Alliances

Merck Serono, Intrexon Enter Exclusive CAR-T Therapy Alliance

Merck Serono gains access to Intrexon's suite of technologies to engineer T-cells

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck Serono and Intrexon Corp. have entered an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T therapies are designed to bind to a target and trigger an immunological attack against the cancer.    Intrexon will use its cell engineering techniques and RheoSwitch platform to develop products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters